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To determine the relative economic impact of al- 
ternative methods of coronary revascularization, 
in-hospital patient accounts were reviewed in 
149 patients undergoing elective coronary angi- 
oplasty (n = SO), coronary atherectomy (n = 72) 
or intracoronary stent placement (n = 27) over 
an is-month period. Clinical and angiographic 
features were similar in the 3 groups, except 
that prior restenosis was seen more often in pa- 
tients undergoing intracoronary stent placement. 
Procedural success, obtained in >90% of pa- 
tients, was independent of the treatment strate- 
gy. Total in-hospital stay was signiftcantly long- 
er in patients undergoing intracoronary stent 
placement than in patients undergoing coronary 
angioplasty and directional atherectomy (4.9 f 
2.4 days vs 1.5 f 1.3 and 2.2 f 3.9 days, re- 
spectively; p <O.OOOl). Furthermore, the total 
in-hospital charges were significantly higher in 
patients undergoing intracoronary stent place- 
ment ($12,574 f $4,564 vs $6,220 f $5,716; 
p <O.OOl) and directional atherectomy ($8,329 
f $8,588 vs $6,220 f $5,716; p <O.Ol) than in 
patients undergoing coronary angioplasty, re- 
flecting overall differences in room costs, labora- 
tory fees and pharmacy fees. The longer in-hos- 
pital stay in the intracoronary stent group was 
primarily attributed to the time required for anti- 
coagulation with coumadin. It is concluded that a 
102 and 34% increase in early hospital charges 
resulted with stenting or directional atherec- 
tomy, respectively, compared with coronary an- 
gioplasty. These increased in-hospital charges 
were chiefly due to the prolonged hospitalization 
time, device cost, laboratory fees and, in patients 
with intracoronary stents, the prolonged time 
needed to achieve systemic anticoagulation. 
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S 
ince its introduction in 1977,’ 2 major limita- 
tions have been noted after coronary angioplasty. 
First, despite pretreatment with antiplatelet 
agents and heparin, abrupt vessel closure develops in 4 
to 7% of cases within 24 hours of the procedure.2,3 Sec- 
ond, delayed restenosis, often requiring a repeat revas- 
cularization procedure, develops in 30 to 40% of pa- 
tients within the subsequent 3 to 6 months4 As a 
result of these shortcomings, alternative mechanical 
techniques such as intracoronary stenting,5-7 atherec- 
tomy,s,9 and laser angioplasty’O have been advocated. 
Whereas initial investigation using these new devices 
has focused on defining safety and clinical efficacy, lit- 
tle attention has been focused on the economic impact 
of these new technologies. Prior retrospective series 
have suggested that coronary angioplasty may be less 
costly than bypass surgery, l l-l5 but no previous study 
has compared the incremental costs of the use of alter- 
native mechanical devices with standard coronary angi- 
oplasty. Therefore, we analyzed in-hospital charges 
from 149 patients undergoing coronary angioplasty, 
coronary atherectomy or intracoronary stenting proce- 
dures. 
METHODS 
Patient population: From January 1, 1989, to June 
30, 1990, 1,014 coronary interventions (coronary angio- 
plasty, 858; directional coronary atherectomy, 116; in- 
tracoronary stent, 40) were performed at the University 
of Michigan Medical Center. For the purposes of this 
analysis, only patients with New York Heart Associa- 
tion class II to III angina undergoing elective coronary 
revascularization, admitted specifically for the proce- 
dure, were selected for the study. To avoid potential 
bias or imbalance of acuity of illness, patients with 
acute myocardial infarction, cardiogenic shock or un- 
stable angina were excluded from the analysis. Patients 
were not excluded with multivessel disease, abnormal 
left ventricular function, or complex lesion morphology 
according to American College of Cardiology/Ameri- 
can Heart Association guidelines. l6 An intention-to- 
treat principle was adapted with inclusion of patient 
data irrespective of the success of the revascularization 
procedure. 
CORONARY ANGIOPLASTY: Random selection of 50 pa- 
tients undergoing coronary angioplasty was performed 
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by reviewing every twelfth case record of the 858 angio- 
plasty cases attempted during the study period. Unless 
contraindicated, all patients were pretreated with aspi- 
rin. After administration of a lO,OOO-unit bolus of hep- 
arin, coronary angioplasty was performed using stan- 
dard methods. k2 Additional heparin was administered 
hourly and, in the presence of thrombus or dissection, a 
heparin infusion was continued for an additional 12 to 
24 hours, maintaining the partial thromboplastin time 
1.5 to 2.5 times control. Patients who developed hemo- 
dynamic instability or prolonged myocardial ischemia 
were admitted to an intensive care unit; patients with- 
out complications were admitted to a specialized care 
unit for observation. Generally, 8Fr sheaths were used 
for coronary angioplasty and 8 hours of bedrest were 
prescribed after sheath removal. 
DIRECTIONAL CORONARY ATHERECTOMY: Of the 112 
patients undergoing coronary atherectomy using the 
Simpson AtheroCathTM (Devices for Vascular Inter- 
vention, Redwood City, California) during the study 
period, 40 were excluded because of unstable symptoms 
requiring hospitalization before atherectomy (n = 37) 
or because audited accounts were unavailable for re- 
view (n = 3). The remaining 72 patients were included 
in the analysis. After premeditation as for patients un- 
dergoing coronary angioplasty, coronary atherectomy 
was performed using an 11Fr sheath by the method 
previously described. I7 After atherectomy, in the ab- 
sence of ischemic complications or coronary dissection, 
patients were admitted to a specialized care unit for 
observation. In general, 11 hours of bedrest were pre- 
scribed after sheath removal. 
INTRACORONARY STENT PLACEMENT: Of the 40 pa- 
tients undergoing stent implantation during the study 
period, 13 were excluded owing to unstable symptoms 
requiring hospitalization at the time of intracoronary 
stent placement (n = 11) or because audited accounts 
were unavailable for review (n = 2). The 27 remaining 
patients composed the study group. In addition to aspi- 
rin and a calcium antagonist, all patients undergoing 
intracoronary stent placement were pretreated with di- 
pyridamole and intravenous dextran beginning 4 hours 
before the procedure. After predilation using standard 
angioplasty methods, intracoronary stent placement 
(Palmaz-Schatz Stent, Johnson and Johnson Interven- 
tional Systems, Warren, New Jersey) was performed 
using previously described methods5,rs After stent im- 
plantation, patients continued to receive intravenous 
heparin until adequate oral anticoagulation could be 
obtained with coumadin (prothrombin time 1.5 times 
control). A 9 to 11Fr sheath was used for stent place- 
ment and was removed within 12 hours after intracoro- 
nary stent placement. In the absence of bleeding at the 
periaccess site, 9 to 11 hours bedrest after sheath re- 
moval were recommended. 
Procedural success and in-hospital complications: 
Procedural success was defined as a final diameter ste- 
nosis <50% and the absence of in-hospital ischemic 
complications, including coronary bypass surgery, myo- 
cardial infarction or abrupt closure. Significant bleed- 
ing complications were defined by a decrease in the he- 
matocrit to <25% or those requiring a blood transfu- 
sion. Hematomas were defined as a >4 cm X 4 cm 
collection of subcutaneous collection of blood at the 
periaccess site. 
Analysis of procedural charges: After patient dis- 
charge, the audited in-hospital accounts of the 149 pa- 
tients used in this analysis were reviewed; only patient 
expenditures directly related to the procedure per- 
formed were included. During the study period of 1989 
to 1990, the cost/charge ratio for all services at the 
University of Michigan Medical Center was 0.76. 
CARDIACCATHETERIZATIONCHARGES: Procedure dura- 
tion (in hours) was used to estimate personnel and 
equipment allocation for each of the 3 methods of 
revascularization and a time-adjusted catheteriza- 
tion room charge was determined. Additional charges 
within the cardiac catheterization laboratory included 
charges for intravascular sheaths, guiding catheters and 
balloon dilatation catheters. Under the investigational 
protocols operational during the study period, expendi- 
tures for intracoronary stents and atherectomy devices 
were not applied to individual patient accounts, but 
were borne directly by the hospital. To estimate the 
total procedural costs, the hospital charges by the inves- 
tigational device manufacturer were added individually 
to the cardiac catheterization charges. During the study 
period, per patient hospital charges were $1,095 for 
the atherectomy equipment (atherectomy device, $850; 
guiding catheter, $130; motor drive unit, $90; hemo- 
static valve, $25) and $1,000 for each intracoronary 
stent. Professional fees for any procedure and charg- 
es for out-patient services were not included in the 
analysis. 
PHARMACY CHARGES: During the hospitalization peri- 
od, pharmacy charges covering intravenous fluids and 
medications including aspirin, a calcium antagonist and 
analgesics were tabulated for all patients. In patients 
with intracoronary stents, the charge for oral coumadin 
and dextran were also added. 
LABORATORY CHARGES: Routine plasma chemistries 
and hematologic profiles were obtained in all patients 
before and after the procedure. Coagulation profiles in- 
cluding a thrombin clotting time and heparin units 
were obtained in patients who continued to receive in- 
travenous heparin after the procedure and in patients 
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TABLE I Clinical and Angiographic Features Before 
Revascularization 
Coronary Directional lntracoronary 
Angioplasty Atherectomy Stenting 
Feature (n = 50) (n = 72) (n = 27) 
Age (years) 60? 12 58+- 11 
Gender (% men) 33 (66) 56 (78) 2: (LY 
Coronary risk factors 
Cigarette smoking (%I 
Systemic hypertension z: I:;; % It;; 7 IZ 
(%) 
Diabetes mellitus (%I 5 (10) 10 (14) 5 (18) 
Hypercholesterolemia 24 (48) 44 (61) 16 (59) 
(%) 
Family history (%) 23 (46) 46 (64) 17 (63) 
Prior cardiac history 
Previous infarction (%I 17 (34) 
Coronary bypass (%) 
Prior coronary angio- :: I%; 
:; Ki; l: I%* 
22 (31) 25 (93)* 
plasty (%) 
Time from angioplasty 6.5 2 4.6 7.5 +- 9.0 4.8 +- 4.4 
(mos) 
Multivessel disease (%I 20 (40) 28 (39) 13 (48) 
Target artery 
Left anterior descending 17 (34) 4 (611 7 (25) 
(%I 
Right coronary (%) 
Left circumflex (%) :‘: l% ? Kl; 2 12 
Saphenous vein graft 2 (4) 3 (4) 3 (11) 
Leriain (%) 0 (0) l(1) l(4) 
Medication 
Nitroglycerin (%I 
Calcium antagonists % I% z: Ki; 5 I2 
(%) 
p blockers (%) 14 (28) 13 (18) 12 (43) 
Aspirin (%I 50 (100) 67 (93) 25 (93) 
*p <0.05 for intracoronary stent versus angioplasty/atherectomy. 
tp < 0.05 for atherectomy versus angioplasty/intracoronary stent. Systemic hyper- 
tension defined by a diastolic blood pressure > 105 mm Hg; hypercholesterolemia 
defined by a total serum cholesterol > 240 mg/dl. 
1 
undergoing intracoronary stent placement, until thera- 
peutic oral anticoagulation was achieved. Remaining 
laboratory tests and any indication for blood transfu- 
sion was left to the discretion of the individual physi- 
cians caring for the patients. 
ROOM CHARGES: In general, patients were admitted to 
a specialized care unit with continuous cardiac monitor- 
ing after the procedure. Daily hospital charges for this 
classification of hospital bed were $606 to $656/day. 
Patients with prolonged myocardial ischemia, hemody- 
namic compromise or other cardiac complications 
admitted to the intensive care unit were charged 
$l,545/day. 
INCIDENTAL CHARGES: All patients also received 
accounts for incidental charges. These charges includ- 
ed the charge for telemetry, respiratory care therapy 
equipment, extra lines required for intravenous therapy 
and use of infusion pumps. 
Ambulatory status during hospitalization: To deter- 
mine the relative patient dependency during hospital- 
ization, medical records were reviewed to determine 
ambulatory status of patients during hospitalization. 
The following classification was used: (1) bedrest- 
sheath in place - time from completion of the proce- 
TABLE II Procedural Success and In-Hospital Complication 
Rate 
Coronary Directional lntracoronary 
Angioplasty Atherectomy Stenting 
Event (n = 50) (n = 72) (n = 27) 
Procedural outcome 
Primary success (%) 46 (92) 66 (92) 2 (93) 
Primary failures (%) 3 (6) 5 (7) 25 (7) 
Urgent CABG (%I 1 (2) l(l) 0 (0) 
In-hospital complications 
Subacute closure (%) 1 (2) 0 (0) 1 (4) 
Recath-chest pain (%) 0 (0) 0 (0) 5 (19) 
Femoral artery 
Bleed (%) 0 (0) 0 (0) 4 c151* 
Hematoma (%) l(2) 6 (8) 3 c111* 
Vascular repair 0 (0) l(l) 2 (7) 
CNS complication (%) 0 (0) l(l) 0 (0) 
*p < 0.05 compared with coronay angioplasty and directional atherectomy. 
CABG = coronary artery bypass grafting; CNS = central netvo~s system event; 
Recath = repeat cardiaccatheterization. 
dure until the sheath removal; (2) bedrest-sheaths re- 
moved - period after the sheath removal until ambu- 
lation, and including any time required because of 
hematomas or femoral artery bleeding; and (3) ambu- 
latory - time from ambulation until discharge, includ- 
ing the period of oral anticoagulation in patients under- 
going intracoronary stent placement. 
Statistical analysis: Continuous variables are ex- 
pressed as mean f 1 standard deviation. Differences 
between continuous variables were analyzed using anal- 
ysis of variance for multiple comparisons and differ- 
ences in frequencies were analyzed using chi-square 
analysis. Nonparametric analysis was applied when ap- 
propriate. Differences at p <0.05 were considered sig- 
nificant. 
RESULTS 
Clinical characteristics, procedural outcome and in- 
hospital complications: Clinical findings in patients un- 
dergoing coronary revascularization are listed in Table 
I. Procedural success obtained in >90% of procedures 
did not vary significantly by treatment strategy (Table 
II). Repeat angiography for recurrent chest pain in pa- 
tients undergoing intracoronary stent placement was 
performed for chest discomfort and any suggestive elec- 
trocardiographic changes of ischemia. In the 5 patients 
undergoing repeat coronary arteriography for recurrent 
chest pain in this group, abrupt closure was demon- 
strated in only 1. Femoral artery rebleeding and hema- 
toma formation were more frequent in patients under- 
going intracoronary stent placement, although hema- 
toma formation was not significantly different from pa- 
tients undergoing directional atherectomy. Notably, 
patients undergoing intracoronary stent placement had 
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significantly longer periods of bedrest-sheaths in place, 
bedrest-sheaths removed, and in-hospital ambulatory 
status than patients undergoing coronary angioplasty or 
directional atherectomy (Figure 1). 
In-hospital charge analysis: Although the in-hospi- 
tal stay was similar for patients undergoing coronary 
angioplasty and directional atherectomy, significantly 
longer hospital stays were required in patients undergo- 
ing intracoronary stent placement (Table III). This 
longer in-hospital period was associated with higher 
room charges, laboratory and pharmacy fees, and total 
hospital charges in the intracoronary stent group. Thus, 
the total in-hospital charges for intracoronary stent 
placement was slightly more than double that of stan- 
dard coronary angioplasty and >30% greater than di- 
rectional atherectomy (p <O.OOl ) (Figure 2). Direc- 
tional coronary atherectomy was also associated with 
34% higher hospital charges than coronary angioplasty. 
DISCUSSION 
Because of limitations of coronary angioplasty, in- 
cluding abrupt vessel closure2S and late restenosis,4 al- 
ternative methods of coronary revascularization have 
been investigated. 5-10 Despite encouraging angiograph- 
ic and clinical results using these alternative tech- 
niques,19 little attention has been focused on the poten- 
tial economic cost of their more widespread application. 
To define the relative resource allocation required by 
coronary angioplasty and 2 of these alternative meth- 
ods, directional atherectomy and intracoronary stent- 
TABLE 111 Duration of Hospitalization and Itemized In-Hospital Charges 
Coronary Directional 
Angioplasty Atherectomy 
(n = 50) (n = 72) 
lntracoronary 
Stenting 
(n = 27) 
Hospital duration (days) 
In-hospital charges ($) 






Total charges 6) 
% Increase over coronary 
angioplasty 
1.5 r 1.3 
4,044 k 974 
Included 
158 + 231 
290 f 470 
964 k 1,019 
763 k 3,730 
6,220 -f- 5,716 
2.2 -+ 3.9 
3,406 + 1,289 
1,260 + 386 
313 + 787 
582 2 1,144* 
1,703 2 2,961 
1,066 e 4,032 
8,329 + 8,588* 
+34 
4.9 + 2.4*t 
5,518 k l,546*t 
1,150 k 362 
454 2 287*t 
989 2 805*t 
3,376 k 2,308*t 
1,087 -f- 887 
12,574 -+ 4,564*t 
+103 
*p co.01 compared with coronary angioplasty; tp co.01 compared with directional atherectomy. 











FIGURE 1. Ambulation status of patients undergoing nonsurgical coronary revascularization. Pat&s undergoing intracoronary 
stenting had significantly longer in-hospital stays, primarily refiected by longer periods of bedrest with sheaths out and ambula- 
tiin before hospital discharge than coronary angioplasty or directional atherectomy. 
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ing, the present study was performed by reviewing the age true economic cost of a service. l5 To compensate 
in-hospital accounts of 149 patients undergoing elective for losses in one area, hospitals may “cost-shift,” charg- 
revascularization using one of these techniques. Com- ing more than the true economic cost for other services 
pared with patients undergoing coronary angioplasty, that are more substantially reimbursed by third-party 
in-hospital charges were 102% higher in patients under- payers.20 
going intracoronary stent placement and 34% higher in Hlatky et a121 used standard cost-accounting meth- 
patients undergoing directional atherectomy. Signifi- ods to relate direct costs plus allocated hospital over- 
cantly longer hospitalization periods required in pa- head, an index of true economic cost, to hospital charg- 
tients undergoing stent placement accounted for most es. In the 389 patients evaluated, direct costs plus allo- 
of the increased in-hospital charges. cated hospital overhead were 0.78 of hospital charges, 
Prior studies estimating the economic costs of coro- not dissimilar from the estimated cost-charge ratio of 
nary angioplasty have, in general, reviewed audited in- 0.76 in the present study. Provided that hospital charg- 
hospital and 1 -year total charges. 12-15 However, the use es for each service would be discounted by the same 
of hospital charges as a substitute for true economic cost/charge ratio - an assumption that may be inac- 
costs may have important limitations.20 In-hospital curate in the event of “cost-shifting” - the results of 
charges are often discounted by third-party payers, so the present study would suggest that intracoronary 
that reimbursement may actually be less than the aver- stent placement may require more than twice the im- 
TABLE IV Prior Trials Comparing Coronary Angioplasty and Coronary Bypass Surgery 
Hospital Days In-Hospital Charges ($1 
No. of No. of Follow-Up 
Study Vessels pts. PTCA CABG PTCA CABG Ratlo Period 
Jang (1984111 Single 361 4%2 12 2 5 5,313 f 2,159 15,580 2 2,159 2.9 In-hospital 
Reeder (1984)” Single 168 9.4 13.1 11,384 13,387 1.2 1 year 
Kelly (1985)13 Single 112 5k4 10 f 4 7,689 13,559 1.8 1 year 
Black (1988114 Multi- 200 5 13 9,138 22,771 2.5 1 year 
Barbash (1986)15 Multi- 52 625 - 8,500 f 4,700 * - In-hospital 
Hlatky (1990)21 Single 389 7k4 14 t 6 9,556 +- 5,251 19,644 + 9,157 2.0 In-hospital 
Present study Multi- 50 2kl - 6,220 +- 5,176 * - in-hospital 
*Includes only elective coronary angioplasty. 








-- Directional Atherectomy ,,i 





1 2 3 4 5 ihr- 
Hospital Stay (In Days) 
FIGURE 2. Average in-hospital cumulative daily charges for patients undergoing nonsurgical revascularizatton. Patients undsr- 
going intracoronary stenting had significantly higher in-hospital charges throughout the hospital period. 
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mediate in-hospital economic resources as standard cor- 
onary angioplasty; directional coronary atherectomy 
may require nearly 40% more resources than coronary 
angioplasty. 
Several factors influenced in-hospital charges for the 
3 treatment strategies. The postprocedural in-hospital 
stay for patients undergoing balloon angioplasty (2 f 1 
days) was substantially shorter than the in-hospital stay 
reported in prior studies (range 5 to 14 days) (Table 
IV). Furthermore, accounting for 1989 dollars, the in- 
hospital charges for balloon angioplasty were also lower 
in the present report, reflecting the elective nature of 
the study population, the same day admission policy for 
coronary angioplasty, and more rapid hospital dis- 
charge with uncomplicated patients. As a result, the 
comparatively high in-hospital charges with directional 
atherectomy and intracoronary stent may simply reflect 
the evolution of lower in-hospital charges associated 
with coronary angioplasty. In fact, the 5-day hospital 
stay for patients with an intracoronary stent in the pres- 
ent study is not substantially different from the length 
of stay with historic cohorts of coronary angioplasty 
(Table IV). Vascular complications occurred more of- 
ten in patients undergoing stent placement and direc- 
tional atherectomy than in patients undergoing coro- 
nary angioplasty, often prolonging the hospitalization 
period. Whereas increased operator experience and 
modification in equipment design may reduce the noted 
vascular complication rate, the requirement for system- 
ic anticoagulation in patients undergoing stent place- 
ment necessitates longer periods of in-hospital observa- 
tion. Potentially, the development of nonthrombogenic 
stents will permit shorter periods of in-hospital observa- 
tion in the future. 
Admittedly, the present study examines only the im- 
mediate in-hospital charges associated with coronary 
angioplasty, directional atherectomy and intracoronary 
stenting. Estimation of the overall economic cost of 
these procedures would require inclusion of the subse- 
quent “induced-costs” associated with late restenosis.** 
In a previous study examining the economic costs asso- 
ciated with coronary angioplasty, restenosis was associ- 
ated with $10,641 of additional hospitalization charges, 
although the number of patients treated with coronary 
bypass surgery for restenosis was high.‘* Despite multi- 
ple pharmacologic approaches aimed at its prevention, 
restenosis still develops in up to 40% of patients within 
the 3 to 6 months after coronary angioplasty.4 Al- 
though it is hoped that restenosis will be lower using 
directional atherectomy and intracoronary stenting, it 
has been reported in patients undergoing these proce- 
dures.17Js A definitive reduction in restenosis and asso- 
ciated induced-costs using these techniques will require 
randomized trials. 
Several previous studies have compared hospital 
charges associated with coronary angioplasty and coro- 
nary bypass surgery (Table IV), convincingly demon- 
strating the potential economic savings of coronary an- 
gioplasty in patients with single11~12 and multivessel cor- 
onary artery disease. 14~15,21 Whereas the duration of 
follow-up has varied in these different studies, the ratio 
of hospital charges associated with coronary bypass sur- 
gery to coronary angioplasty has ranged from 1.2 to 
2.9. Notably, many patients undergoing intracoronary 
stent placement in the present study had unsuccessful 
coronary angioplasty 1 or more times. Before introduc- 
tion of the intracoronary stent, these patients would 
have been candidates for coronary bypass surgery 
alone, and compared with surgical patients from these 
historic controls, the in-hospital days and hospital 
charges associated with intracoronary stent placement 
are still quite favorable. 
The present study has several important limitations. 
First, these comparative data are derived from a non- 
randomized study with new device use in a relatively 
early stage of development. Modifications in equipment 
design and operator technique may result in future re- 
ductions of in-hospital charges for these alternative de- 
vices. Second, as previously noted, the present study in- 
cludes only immediate in-hospital charges, and does not 
include either charges associated with late restenosis, 
charges associated with the increased surveillance asso- 
ciated with intracoronary stents such as coagulation 
profile monitoring required during 2 to 3 months of 
anticoagulation, or the social impact of these devices on 
patient lifestyle and back-to-work status. Therefore, the 
long-term economic benefits of these devices may not 
be fully realized. Finally, the technique of coronary an- 
gioplasty is in constant evolution. Whereas patient se- 
lection criteria have broadened, hospitalization days 
have shortened and in-hospital charges have been low- 
er. Similarly, the major source of increased in-hospital 
charges in patients undergoing intracoronary stent 
placement in the present study was a prolonged in-hos- 
pital stay, partially attributed to an increased bleeding 
complication rate and requirement for systemic anti- 
coagulation associated with intracoronary stenting. Ear- 
lier sheath removal and alternative anticoagulation 
schemes, such as an adjusted subcutaneous dose of hep- 
arin23 and bedside coagulation monitoring, and the 
development of nonthrombogenic intracoronary stents 
may substantially reduce the required hospitalization 
time in future studies. 
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